Fig. 3.

Impact of vaccination alone or in combination with interventions (universal cloth, surgical, or double mask use, ventilation [2 ACH]) on infection risk following 8 h cumulative exposure to an infected worker at 1 m distancing. No immunity reference group represents infection risk with baseline ACH = 0.1 in the absence of vaccination or any interventions. For the partial and full immunity scenarios, both the infected and susceptible workers were assumed to be vaccinated with at least one of two doses. Under these scenarios, the infected worker represented a rare breakthrough infection event in which vaccination led to reduced virus shedding for the infected worker (2.8-fold reduction) (Levine-Tiefenbrun et al., 2021). For the partial immunity scenario, the vaccinated susceptible worker had a 52–74% reduction in infection risk representative of a single dose of the two-dose mRNA vaccine series, or reduced vaccine efficacy against SARS-CoV-2 variants (FDA, 2021a, 2021b, Polack et al., 2020). For the full immunity scenario, the vaccinated susceptible worker had a 77–99% reduction in infection risk representative of ≥14 days after the second dose derived from vaccine effectiveness data for the Johnson & Johnson/Janssen, Pfizer-BioNTech, Moderna, and AstraZeneca vaccines (Corchado-Garcia et al., 2021; Swift et al., 2021). Results are presented as the median risk values with 5th and 95th percentile bars.